Advertisement

Journal of Thermal Analysis and Calorimetry

, Volume 78, Issue 1, pp 47–54 | Cite as

Use of isothermal microcalorimetry in pharmaceutical preformulation studies, Part I. Monitoring crystalline phase transitions

  • N. Murti Vemuri
  • Zofia Chrzan
  • Raghu Cavatur
Article

Abstract

Solid-state transformation kinetics of two crystal forms of a synthetic tetrapeptide was monitored by isothermal microcalorimetry and complementary solid-state analytical techniques. Form B, the crystal form obtained from the synthetic process transformed to Form D upon exposure to higher relative humidity conditions (>60% RH). The transformation occurred rapidly at higher temperature, and relative humidities. An intermediate phase of very low crystallinity (amorphous-like phase) was observed when transformation was slow. Form D was observed to be physically stable at higher relative humidities and thus the preferred crystal form for development. Exposure of Form B to high relative humidity was the only process through which Form D was obtained. Optimal conditions for transformation of Form B to Form D were determined by microcalorimetric experiments and were used for larger scale processing of Form B to Form D.

crystallization microcalorimetry polymorphism amorphous solid-state transformation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. J. W. Grant, Theory and origin of polymorphism, in H. G. Brittain (Ed.), Polymorphism in Pharmaceutical Solids, Vol. 95, Marcel Dekker, New York 1999, pp. 1-33.Google Scholar
  2. 2.
    S. Byrn, R. Pfeiffer, M. Ganey, C. Hoiberg and G. Poochikian, Pharm. Res., 12 (1995) 945.CrossRefGoogle Scholar
  3. 3.
    M. Angberg, C. Nystrom and S. Castensson, Int. J. Pharm., 81 (1992) 153.CrossRefGoogle Scholar
  4. 4.
    S. Lindenbaum, Calorimetry in pharmaceutical research and development in J. Swarbrick and J. C. Boylan (Eds), Encyclopedia of Pharmaceutical Technology, Vol. 2, Marcel Dekker Inc., New York 1990, pp. 233-250.Google Scholar
  5. 5.
    A. Burger and R. Ramburger, Microchim. Acta [Wein], II (1979) 259.CrossRefGoogle Scholar
  6. 6.
    J. S. G. Cox, G. D. Wodaard and W. C. McCrone, J. Pharm. Sci., 60 (1971) 1458.Google Scholar
  7. 7.
    E. B. Vadas, P. Toma and G. Zografi, Pharm. Res., 8 (1991) 148.CrossRefGoogle Scholar
  8. 8.
    J. W. Mullin, Crystallization, 3rd. Butterworth Heinemann, London, UK 1993, pp. 172-201.Google Scholar
  9. 9.
    I. C. Paul and D. Y. Curtin, Acc. Chem. Res., 6 (1973) 217.CrossRefGoogle Scholar
  10. 10.
    S. R. Vippagunta, H. G. Brittain and D. J. W. Grant, Adv. Drug Del. Rev., 48 (2001) 3.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publisher/Akadémiai Kiadó 2004

Authors and Affiliations

  • N. Murti Vemuri
    • 1
  • Zofia Chrzan
    • 1
  • Raghu Cavatur
    • 1
  1. 1.Aventis Pharmaceuticals Route 202-206 SUSA E-mail

Personalised recommendations